Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Sodium Ibandronate Injection.

Function and indication:
Pathological (abnormal) increase in blood calcium (hypercalcemia) caused by tumors.
Dosage and administration:
1. Intravenous administration of this product should usually be performed in a hospital. The doctor should determine the dosage based on the following factors. 2. The patient must be fully hydrated with normal saline before receiving treatment with this product. The severity of hypercalcemia and the type of tumor should be considered at the same time. For most patients with severe hypercalcemia (serum calcium concentration corrected by albumin ≥3mmol/L or ≥12mg/dL), a single dose of 4mg is sufficient. For moderate hypercalcemia (serum calcium concentration corrected by albumin ≤3mmol/L or ≤12mg/dL), a single dose of 2mg is effective. The highest single dose in clinical trials was 6mg, but it did not improve the efficacy. 3. Note: Albumin-corrected serum calcium concentration (mmol/L) = serum calcium concentration (mmol/L) – 0.02 × albumin concentration (g/L) + 0.8 or albumin-corrected serum calcium concentration (mmol/dL) = blood calcium concentration (mmol/L) + 0.8 × “4 – albumin concentration (g/dL)” 4. The blood calcium level of most patients with hypercalcemia drops to the normal range within 7 days after treatment with this product. 5. The median time to relapse after a single dose of 2mg and 4mg (serum calcium concentration corrected by albumin 3mmol/L) is 18 to 19 days, and the median time to relapse after a single dose of 6mg is 26 days. 6. Currently, only a few patients (50 cases) have received a second intravenous treatment with this product for hypercalcemia. 7. Repeated medication may be considered in case of recurrent hypercalcemia and poor efficacy of the first treatment. 8. Concentrated injection of this product should be administered by intravenous drip. When taking the medicine, add the drug to 500ml of isotonic sodium chloride solution or 500ml of 5% glucose solution and drip it intravenously for 2 hours. 9. Precautions To avoid incompatibility, concentrated injection of Bonlorli is only allowed to be mixed with isotonic sodium chloride or 5% glucose solution, and cannot be mixed with calcium-containing solution for intravenous infusion. 10. Special instructions It is not recommended to administer this product through the artery to treat hypercalcemia. If it is accidentally administered through the arterial or extravenous route, it may cause tissue damage. Therefore, it is necessary to ensure that this product is administered intravenously. Precautions for the use of ampoules Hold the ampoule with the blue dot upward and shake it or tap it with your fingers to ensure that the liquid in the neck of the bottle accumulates in the bottle body. Break the ampoule at the neck of the bottle. Generally, Bonlorli is only administered once. However, it can be administered repeatedly if necessary.
Adverse reactions:
1. Fever is most common after intravenous infusion of this product. Individual reports of flu-like syndrome including fever, chills, bone and/or muscle pain. In most cases, these symptoms disappear within a few hours or days and no special treatment is required. 2. Reduced renal calcium excretion is usually accompanied by a decrease in serum phosphorus levels, and generally no treatment is required. Blood calcium concentration can drop below normal levels. 3. Intolerable gastrointestinal reactions occur in some cases. Asthma patients who are sensitive to acetylsalicylic acid may induce bronchospasm (wheezing, dyspnea) when receiving other bisphosphonates. 4. If other reactions other than therapeutic effects occur, especially side effects not listed in the drug instructions, the patient should promptly notify the doctor or pharmacologist.
Contraindications:
1. It is contraindicated in patients with hypocalcemia. 2. Those who are known to be allergic to ibandronic acid or any of the excipients. 3. It is contraindicated in patients with severe kidney disease (such as renal insufficiency, blood creatinine 5mg/dL, or 442umol/L).

Ibandronate sodium injection is used to treat postmenopausal osteoporosis; to treat bone pain caused by osteolytic bone metastases of malignant tumors; to treat hypercalcemia caused by malignant tumors with or without bone metastases.

Share:

Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.